Clinical trials
Prostate clinical trials
Below are recruiting prostate clinical trials, each written for real people, not researchers. We’re tracking 1,368 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07755592Recruiting
Using a blood test to find prostate cancer early
This study uses a simple blood test to look for microRNA patterns that may help spot prostate cancer earlier and avoid unnecessary biopsies. If you have elevated PSA or suspicious findings, this test might give more information about your risk.
ShanghaiAges 18 years+ - NCT06067841RecruitingPhase 1
New drug for advanced prostate cancer
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
Palo Alto, CaliforniaAges 18 years+ - NCT07450599RecruitingPhase 2
Darolutamide plus hormone therapy before prostate cancer surgery
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
Hefei, AnhuiAges 18 years+ - NCT07543055RecruitingPhase 1
CAR T-Cell Therapy for Advanced Prostate Cancer
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Hackensack, New JerseyAges 18 years+ - NCT07493512RecruitingPhase 1
Study of xaluritamig for metastatic prostate cancer
This trial tests a new drug called xaluritamig for men with metastatic prostate cancer that is resistant to hormone therapy. It is designed for those who have already tried certain hormone pills and one type of chemotherapy, and aims to see if the drug can shrink tumors or slow cancer growth.
Denver, ColoradoAges 18 years+ - NCT06864533Recruiting
Chemotherapy after surgery for aggressive prostate cancer
This trial tests whether adding chemotherapy after standard treatment helps people with a very aggressive type of prostate cancer (Gleason score 9-10). It is designed for those who have not had their cancer spread to distant parts of the body and are healthy enough to handle chemotherapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05610852Recruiting
Surgery through the bladder opening versus focused ultrasound for prostate cancer
This trial compares two ways to treat early prostate cancer: a single small surgery through the bladder versus high-intensity focused ultrasound (HIFU). It aims to see which approach works better while keeping side effects and recovery acceptable.
Cleveland, OhioAges 19 years+ - NCT07075666Enrolling by invitation
Early detection of prostate cancer in Syrian men
This trial aims to find prostate cancer early in Syrian men living in the middle region of the country. If you join, you'll help doctors learn better ways to screen for the disease, which may lead to earlier and more effective treatment.
HomsAges 40–65 - NCT06834321RecruitingPhase 2
Homoharringtonine with hormone therapy before prostate surgery
This trial tests a new combination of a chemotherapy drug (homoharringtonine) and hormone therapy (androgen deprivation) given before surgery to shrink prostate cancer that has spread a little or is advanced. The goal is to see if this approach can help control the cancer better before the prostate is removed.
Nanjing, JiangsuAges 18–85 - NCT06736054RecruitingPhase 1
Testing a new PSMA imaging agent for prostate cancer
This trial tests a new radioactive imaging agent (61Cu-NODAGA-PSMA) to see if it can help find prostate cancer cells. It's for people with prostate cancer that shows up on a PSMA PET/CT scan.
Irvine, CaliforniaAges 18 years+ - NCT06626022RecruitingPhase 3
Micro-ultrasound vs MRI for prostate cancer screening
This trial compares two imaging methods, high-resolution micro-ultrasound and MRI, to see which is better at finding prostate cancer in men who have not had a biopsy before. If you are between 50 and 70 with an elevated PSA or abnormal exam, you may be able to join.
Los Angeles, CaliforniaAges 50–70 - NCT06419348RecruitingEarly Phase 1
Imaging scan for PSMA in prostate cancer
This trial uses a special imaging scan (SPECT) to look for a protein called PSMA on prostate cancer cells. The goal is to see how well the imaging agent (99mTc-QULIC-5-P1) finds cancer, which may help guide future treatment decisions.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06325774Recruiting
Shorter radiation for localized prostate cancer
This trial tests a shorter, more intense course of radiation (hypofractionated radiotherapy) for men with localized prostate cancer that hasn't spread. It aims to see if this treatment is safe and effective and may reduce the number of hospital visits.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06305390RecruitingPhase 2
PSMA PET/MRI for prostate cancer diagnosis
This trial tests a new, all-in-one PET/MRI scan to see if it can better find aggressive prostate cancer in men who need a biopsy. It may help avoid unnecessary biopsies and give a clearer picture of your condition.
Milan, MilanoAges 18 years+ - NCT06265519Recruiting
Urine markers for enlarged prostate check
This study looks at two natural substances in urine (BDNF and NGF) to see if they can help doctors understand how the lower urinary tract is working in men with an enlarged prostate. It is a simple, non-invasive test that may lead to better ways to diagnose and treat bladder problems.
IstanbulAges 50–80 - NCT06201078RecruitingPhase 2
Second radiation for prostate cancer that returns locally
This trial tests a second round of precise, high-dose radiation (stereotactic body radiotherapy) for men whose prostate cancer has come back only in the prostate after their first radiation treatment. It aims to control the recurrence with fewer side effects.
GliwiceAges 18–80 - NCT05942001RecruitingPhase 1
Testing an investigational drug for advanced prostate cancer
This Phase 1 trial tests HRS-5041 in people with metastatic castration-resistant prostate cancer (prostate cancer that keeps growing despite lower testosterone). It aims to see if the drug can be given safely and whether it may help control the cancer after prior standard treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06134232RecruitingPhase 2
Extra sipuleucel-T after Provenge for prostate cancer
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Tuscon, ArizonaAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT05563558RecruitingPhase 2
Testing pembrolizumab plus chemotherapy for aggressive metastatic prostate cancer
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
MadridAges 18 years+ - NCT05603559RecruitingEarly Phase 1
Study of radioactive PSMA-targeting treatment for advanced prostate cancer
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
Beijing, Beijing MunicipalityAges 18–90 - NCT05495633Recruiting
Tracking outcomes after Rezum treatment for prostate blockage
This trial is collecting information about how well Rezum water-vapor treatment works for men with prostate blockage and urinary symptoms. It’s mainly focused on whether different kinds of patients do well, using surveys and clinic follow-up, not on changing your treatment plan.
GrazAges 18 years+ - NCT05010343RecruitingPhase 2
Carbon ion radiation guided by scans for prostate cancer
This Phase 2 trial tests whether using detailed scans (PSMA PET/CT and MRI) to guide carbon ion radiation—delivered in a focused way—can treat localized prostate cancer. It may help target the treatment more precisely while avoiding areas that are not involved.
ShanghaiAges 45–85 - NCT05242744Recruiting
PET/CT scan testing for spread in metastatic prostate cancer
This study tests how well an FTT PET/CT scan can detect and measure metastatic (spread) prostate cancer. It may help your care team decide on the best next treatment plan, especially if you need to change or start therapy.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Prostate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate?
- Yes. Clin2 currently lists 1,368 recruiting prostate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.